Biogen is a biopharmaceutical company focused on discovering, developing and delivering therapies for people living with neurological and neurodegenerative diseases, including in areas of multiple sclerosis (MS) and neuroimmunology, Alzheimer's disease and dementia, movement disorders, including Parkinson's disease, and neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis. The company's marketed products include TECFIDERA, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA and FUMADERM for the treatment of severe plaque psoriasis.
Catalent is a holding company. Through its subsidiaries, the company is a provider of delivery technologies and development solutions for drugs, biologics and consumer health products. The company operates in four segments: Softgel Technologies, which provides formulation, development and manufacturing services for soft capsules; Biologics and Specialty Drug Delivery, which provides drug substance development and manufacturing; Oral Drug Delivery, which provides various formulation development and manufacturing technologies; and Clinical Supply Services, which provides manufacturing, packaging, storage, distribution, project management, and inventory management for drugs and biologics in clinical trials.
Evotec is a holding company engaged as a drug discovery solutions company providing drug discovery capabilities to pharmaceutical and biotechnology companies as well as to academic institutions. These drug discovery solutions are provided in form of fee-for service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Co. is primarily involved in the areas of neuroscience, pain, metabolic diseases, oncology and inflammation. Co. provides its drug discovery activities under the banners of EVT Execute, EVT Integrate and EVT Innovate. Co.'s operations are divided into two segments: EVT Execute and EVT Innovate.
Lonza supplies services and products that range from active pharmaceutical ingredients and stem-cell therapies to drinking water sanitizers, from vitamin B compounds and organic personal care ingredients to agricultural products, and from industrial preservatives to microbial control solutions. Co. operates in two segments: Lonza Pharma & Biotech, which clusters all of Co.'s offerings for pharmaceutical markets, focuses on providing custom development, custom manufacturing, cell therapy, viral therapeutics and bioscience solutions; and Lonza Specialty Ingredients, which includes offerings in its consumer care, agro ingredients, industrial solutions, wood protection and water treatment.
Samsung Biologics is engaged in the manufacture of biological products. Co. provides CMO (Contract Manufacturing Organization) services that serve other domestic and international pharmaceutical companies on a contract basis to produce high-tech biomedicine as of the date when the business report is submitted. Co.is also engages in the research & development and commercialization of biosimilar products.
Sartorius Stedim Biotech is a provider of equipment and services for the development, quality assurance and production processes of the biopharmaceutical industry. Co.'s solutions cover fermentation, filtration, purification, fluid management and lab technologies and membrane chromatography, including various conventional lab products to biopharmaceutical laboratories. Co.'s technologies, products and services are used to develop and manufacture medications and vaccines using biological methods. Co.'s products covers all upstream and downstream steps in the production of active pharmaceutical ingredients. It specializes in single-use products and offers technical consulting and services.
Wuxi Biologics Cayman Inc. WUXI BIOLOGICS (CAYMAN) INC. is an investment holding company. The Company along with its subsidiaries is mainly engaged in the discovery, research and development, manufacturing and sales of biologics products. The Company's primary products include the clinical active pharmaceutical ingredients, sterile liquid preparations, freeze-dried preparations, as well as small molecules antibiotics for injection drugs. The Company mainly distributes its products in the United States of America (USA) and the People's Republic of China (PRC) markets.
Provided by our team of experienced analysts, our work is idea driven, based on independence of thought, sector expertise, and firmly focussed on fundamentals and valuation.
New Street Research is an independent, partner-owned, research firm specialising in equity and debt research. Our equity research embraces the following sectors:
We provide debt research on:
Biogen Inc. (BIIB:USA) currently trades well below corporate averages relative to UAFRS-based (Uniform) earnings, with a 7.9x Uniform P/E. At these levels, the market has bearish expectations for the firm, and management may have concerns about clinical trial delays, revenue growth, and aducanumab's approval process Specifically, management may lack confidence in their ability to sustain Q1 financial results, revenue growth, and gross margin stability. Moreover, they may be exaggerating their ability to mitigate coronavirus risks, the growth opportunities in their biosimilar business, and the...
Synergies are often a key part of the story when telecom M&A transactions are announced. But are they actually delivered? We go back and look at past deals to assess both absolute and relative performance and run through our findings in detail.
Our LBPN deep-dive leads us to believe there is considerable upside from new modalities, US & EU onshoring trends, the IBEX platform & the newly signed Moderna alliance. We increase our 2025 group sales forecasts by 13% and EBITDA forecasts by 15%. We are now 10% above consensus EBITDA in 2022 and 8% higher on sales. We do not include the Moderna COVID vaccine in our forecasts but show that it could add ~40% to 2021 EBIT (although adds 2-3% to company NPV). A number of imminent catalysts could boost the shares: LSI spin decision is due any day, MRNA COVID vaccine P2 data in Q320 & the new CEO ...
As we exit Q2, we now have several datapoints that show EU Pharma has been significantly impacted by COVID-19. We show that doctor visits and NBRx were down by around 40% YoY. However, there is considerable variation by therapy area and by clinical setting. Using a risk matrix and analysing >60 of the biggest drugs in EU Pharma, we analyse which companies are most at risk for 2Q20 & therefore will find hitting 2020 guidance to be all the more challenging. We show SAN & AZN are least impacted whilst GSK & Novartis fare worst. Surprisingly, ROG is impacted more than we expected...
We previously predicted that COVID-19 would have a multi-quarter impact on the economy & market expectations for a quick recovery were misplaced. However, due to Government mismanagement, such as late lockdowns, allowing inbound air travel from COVID hotspots, poor testing, limited ability to contact trace and seemingly poor preparedness for a 2nd wave, the impact of COVID-19 could well last into 2022. In this note we provide clear evidence that public confidence is unlikely to return irrespective of whether governments remove all restrictions and that the route out is neither linear nor will ...
Unfortunately, this report is not available for the investor type or country you selected.Browse all ResearchPool reports
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.